Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 7 of 7 citing Issa: Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiec.... (0.07 sec) 

Reading performance is reduced by parafoveal scotomas in patients with macular …


RP Finger, C Issa… - Investigative Ophthalmology & Visual Science, 2009 - ARVO
METHODS. In this prospective controlled cross-sectional observational study, 49
eyes of 26 patients with MacTel type 2 were investigated. Twenty-four eyes of 14
age-matched normal subjects served as the control. Reading acuity and ...
Cited by 3 - Related articles - All 3 versions

Bevacizumab (Avastin) for the Treatment of Ocular Disease


JB Gunther, MM Altaweel - Survey of Ophthalmology, 2009 - Elsevier
The use of intravitreal bevacizumab (Avastin) has greatly expanded since its
introduction into ophthalmic care 3 years ago. A PubMed search on 1 August 2008
revealed 51 ocular disease processes that have been treated with ...
Cited by 2 - Related articles - All 23 versions

Test-retest variability of microperimetry using the Nidek MP1 in patients with macular …


FK Chen, PJ Patel, W Xing, C Bunce, C Egan, … - Investigative Ophthalmology & Visual Science, 2009 - ARVO
METHODS. In this prospective study, 50 patients were enrolled with a range of
macular diseases. One examiner performed two consecutive microperimetry tests
for all patients using the same test strategy. Test–retest variability ...
Related articles - All 5 versions

Issa, Peter Charbel MD; Holz, Frank G. MD; Scholl, Hendrik PN MD

- duanessolution.com [PDF] 
PC Issa, FG Holz, HPN Scholl, G Bonn - Retina, 2009 - duanessolution.com
1. In 1968, Gass published a series of landmark articles describing fluorescein
angiography stud- ies of macular dysfunction secondary to retinal vascular
disease. One of these articles is referred to several times in the ...
Related articles - View as HTML

A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with …


D Karagiannis, I Georgalas, I Ladas, P … - Clinical Interventions in Aging, 2009 - pubmedcentral.nih.gov
A 65-year-old lady presented with decreased vision in her left eye (LE). Best
corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic
juxtafoveal retinal telangiectasis associated with subretinal ...
Related articles - All 6 versions

Systemic antiangiogenic therapy: what goes around…

- duanessolution.com
JS Pulido, S Itty - British Journal of Ophthalmology, 2009 - bjo.bmj.com
Initially, Rosenfeld and his coauthors used the standard dose of intravenous
bevacizumab that was used for colonic carcinoma. They treated a total of 18
patients in an open-labelled trial with infusions given every other week ...
Related articles - All 5 versions

Pharmacokinetics of Bevacizumab after Topical, Subconjunctival, and Intravitreal …


H Nomoto, F Shiraga, N Kuno, E Kimura, S … - Investigative Ophthalmology & Visual Science, 2009 - ARVO
RESULTS. After intravitreal injection in the treated eye, the mean maximum
concentrations (C max ) of bevacizumab in the iris/ciliary body and
retina/choroid were 109,192.6, and 93,990.0 ng/g, respectively, whereas ...
Related articles - All 3 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google